



Theranostic Drug Delivery: Prospects and Problems 2.0

Guest Editor:

Prof. Dr. M. R. Mozafari

Department of Biochemistry and
Molecular Biology, Monash
University, Melbourne, Australia

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editor

Dear Colleagues,

After the success of the first Special Issue on "Theranostic Drug Delivery: Prospects and Problems", in which high-impact papers authored by eminent international scientists were published, we are now aiming to launch the second Special Issue on the topic. As an important aspect of modern medicine, the theranostic approach is the most advanced, scientifically based, and statistically approved therapeutic and diagnostic methodology. Applications in the diagnosis and treatment of viral diseases and different types of cancer are being developed worldwide. We invite innovative research papers and review articles reflecting the fields of in vitro diagnostics and prognostics as well as in vivo molecular therapeutics and molecular imaging. In addition, we welcome manuscripts on biosensors, image-guided therapy, translational medicine, personalized medicine, system biology, and a broad range of biomedical research, which can be applied to enhance theranostic applications.

Prof. Dr. M. R. Mozafari

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI